Fibulin-4 is associated with tumor progression and a poor prognosis in ovarian carcinomas

详细信息    查看全文

• 作者：Jie Chen (1)
  Zhao Liu (2)
  Shuang Fang (3)
  Rui Fang (4)
  Xi Liu (4)
  Yueran Zhao (5)
  XiangXin Li (6)
  Lei Huang (7)
  Jie Zhang (5)
  
  1. Department of Maternal and Child Health Care ; School of Public Health ; Shandong University ; Jinan ; 250012 ; China
  2. Hepatobiliary and Pancreatic Surgery ; Jinan Central Hospital affiliated to Shandong University ; Jinan ; 250013 ; China
  3. Biochemistry & Molecular Biology ; Georgetown University ; Georgetown ; Washington D.C ; 20057 ; USA
  4. Grade 2011 ; Clinical Medicine ; School of Medicine ; Shandong University ; Jinan ; 250012 ; China
  5. Central Laboratory ; Shandong Provincial Hospital affiliated to Shandong University ; Jinan ; 250021 ; China
  6. Department of Haematology ; QiLu Hospital of Shandong University ; Jinan ; 250012 ; China
  7. Department of Pediatrics ; Shandong Provincial Hospital affiliated to Shandong University ; Jinan ; 250021 ; China
  
• 关键词：Fibulin ; 4 ; Ovarian carcinoma ; Angiogenesis ; Prognosis
• 刊名：BMC Cancer
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：15
• 期：1
• 全文大小：3,817 KB
• 参考文献：1. Jemal, A, Siegel, R, Xu, J, Ward, E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: pp. 277-300 CrossRef
  2. Brun, JL, Feyler, A, Chene, G, Saurel, J, Brun, G, Hocke, C (2000) Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 78: pp. 21-7 CrossRef
  3. Cho, KR, Shih, IM (2009) Ovarian cancer. Annu Rev Pathol 4: pp. 287-313 CrossRef
  4. Bast, RC, Hennessy, B, Mills, GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9: pp. 415-28 CrossRef
  5. Chaffer, CL, Weinberg, RA (2011) A perspective on cancer cell metastasis. Science 331: pp. 1559-64 CrossRef
  6. Coticchia, CM, Yang, J, Moses, MA (2008) Ovarian cancer biomarkers: current options and future promise. J Natl Compr Canc Netw 6: pp. 795-802
  7. Vega, S, Iwamoto, T, Yamada, Y (2009) Fibulins: multiple roles in matrix structures and tissue functions. Cell Mol Life Sci 66: pp. 1890-902 CrossRef
  8. Gallagher, WM, Currid, CA, Whelan, LC (2005) Fibulins and cancer: friend or foe?. Trends Mol Med 11: pp. 336-40 CrossRef
  9. Law, EW, Cheung, AK, Kashuba, VI, Pavlova, TV, Zabarovsky, ER, Lung, HL (2012) Anti-angiogenic and tumor-suppressive roles of candidate tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinoma. Oncogene 31: pp. 728-38 CrossRef
  10. Yi, CH, Smith, DJ, West, WW, Hollingsworth, MA (2007) Loss of fibulin-2 expression is associated with breast cancer progression. Am J Pathol 170: pp. 1535-45 CrossRef
  11. Schluterman, MK, Chapman, SL, Korpanty, G, Ozumi, K, Fukai, T, Yanagisawa, H (2010) Loss of fibulin-5 binding to beta1 integrins inhibits tumor growth by increasing the level of ROS. Dis Model Mech 3: pp. 333-42 CrossRef
  12. Hu, Z, Ai, Q, Xu, H, Ma, X, Li, HZ, Shi, TP (2011) Fibulin-5 is down-regulated in urothelial carcinoma of bladder and inhibits growth and invasion of human bladder cancer cell line 5637. Urol Oncol 29: pp. 430-5 CrossRef
  13. Yue, W, Sun, Q, Landreneau, R, Wu, C, Siegfried, JM, Yu, J (2009) Fibulin-5 suppresses lung cancer invasion by inhibiting matrix metalloproteinase-7 expression. Cancer Res 69: pp. 6339-46 CrossRef
  14. Moll, F, Katsaros, D, Lazennec, G, Hellio, N, Roger, P, Giacalone, PL (2002) Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells. Oncogene 21: pp. 1097-107 CrossRef
  15. Greene, LM, Twal, WO, Duffy, MJ, McDermott, EW, Hill, AD, O鈥橦iggins, NJ (2003) Elevated expression and altered processing of fibulin-1 protein in human breast cancer. Br J Cancer 88: pp. 871-8 CrossRef
  16. Bardin, A, Moll, F, Margueron, R, Delfour, C, Chu, ML, Maudelonde, T (2005) Transcriptional and posttranscriptional regulation of fibulin-1 by estrogens leads to differential induction of messenger ribonucleic acid variants in ovarian and breast cancer cells. Endocrinology 146: pp. 760-8 CrossRef
  17. Seeliger, H, Camaj, P, Ischenko, I, Kleespies, A, Toni, EN, Thieme, SE (2009) EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer Res 7: pp. 189-98 CrossRef
  18. Song, EL, Hou, YP, Yu, SP, Chen, SG, Huang, JT, Luo, T (2011) EFEMP1 expression promotes angiogenesis and accelerates the growth of cervical cancer in vivo. Gynecol Oncol 121: pp. 174-80 CrossRef
  19. En-lin, S, Sheng-guo, C, Hua-qiao, W (2010) The expression of EFEMP1 in cervical carcinoma and its relationship with prognosis. Gynecol Oncol 117: pp. 417-22 CrossRef
  20. Hu, B, Thirtamara-Rajamani, KK, Sim, H, Viapiano, MS (2009) Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion. Mol Cancer Res 7: pp. 1756-70 CrossRef
  21. Kanda, M, Nomoto, S, Okamura, Y, Hayashi, M, Hishida, M, Fujii, T (2011) Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Mol Carcinog 50: pp. 571-9 CrossRef
  22. Cheng, YY, Jin, H, Liu, X, Siu, JM, Wong, YP, Ng, EK (2008) Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer. Br J Cancer 99: pp. 2083-7 CrossRef
  23. Wlazlinski, A, Engers, R, Hoffmann, MJ, Hader, C, Jung, V, M眉ller, M (2007) Downregulation of several fibulin genes in prostate cancer. Prostate 67: pp. 1770-80 CrossRef
  24. Xie, L, Palmsten, K, MacDonald, B, Kieran, MW, Potenta, S, Vong, S (2008) Basement membrane derived fibulin-1 and fibulin-5 function as angiogenesis inhibitors and suppress tumor growth. Exp Biol Med (Maywood) 233: pp. 155-62 CrossRef
  25. Hwang, CF, Chien, CY, Huang, SC, Yin, YF, Huang, CC, Fang, FM (2010) Fibulin-3 is associated with tumour progression and a poor prognosis in nasopharyngeal carcinomas and inhibits cell migration and invasion via suppressed AKT activity. J Pathol 222: pp. 367-79 CrossRef
  26. Sadr-Nabavi, A, Ramser, J, Volkmann, J, Naehrig, J, Wiesmann, F, Betz, B (2009) Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer 124: pp. 1727-35 CrossRef
  27. Hu, Y, Pioli, PD, Siegel, E, Zhang, Q, Nelson, J, Chaturbedi, A (2011) EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment. Mol Cancer 10: pp. 123 CrossRef
  28. Kim, EJ, Lee, SY, Woo, MK, Choi, SI, Kim, TR, Kim, MJ (2012) Fibulin-3 promoter methylation alters the invasive behavior of non-small cell lung cancer cell lines via MMP-7 and MMP-2 regulation. Int J Oncol 40: pp. 402-8
  29. Chen, L, Sun, B, Zhang, S, Zhao, X, He, Y, Zhao, S (2009) Influence of microenvironments on microcirculation patterns and tumor invasion-related protein expression in melanoma. Oncol Rep 21: pp. 917-23
  30. Argraves, WS, Greene, LM, Cooley, MA, Gallagher, WM (2003) Fibulins: physiological and disease perspectives. EMBO Rep 4: pp. 1127-31 CrossRef
  31. Berk, DR, Bentley, DD, Bayliss, SJ, Lind, A, Urban, Z (2012) Cutis laxa: a review. J Am Acad Dermatol 66: pp. e1-17 CrossRef
  32. Huang, J, Yamashiro, Y, Papke, CL, Ikeda, Y, Lin, Y, Patel, M (2013) Angiotensin-converting enzyme-induced activation of local angiotensin signaling is required for ascending aortic aneurysms in fibulin-4-deficient mice. Sci Transl Med 5: pp. 1-11 CrossRef
  33. Xiang, Y, Sekine, T, Nakamura, H, Imajoh-Ohmi, S, Fukuda, H, Yudoh, K (2006) Fibulin-4 is a target of autoimmunity predominantly in patients with osteoarthritis. J Immunol 176: pp. 3196-204 CrossRef
  34. Gallagher, WM, Greene, LM, Ryan, MP, Sierra, V, Berger, A, Laurent-Puig, P (2001) Human fibulin-4: analysis of its biosynthetic processing and mRNA expression in normal and tumour tissues. FEBS Lett 489: pp. 59-66 CrossRef
  35. Ying, J, Shan, L, Li, J, Zhong, L, Xue, L, Zhao, H (2012) Genome-wide screening for genetic alterations in esophageal cancer by aCGH identifies 11q13 amplification oncogenes associated with nodal metastasis. PLoS One 7: pp. e39797 CrossRef
  36. Ormandy, CJ, Musgrove, EA, Hui, R, Daly, RJ, Sutherland, RL, Cyclin, D1 (2003) EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 78: pp. 323-35 CrossRef
  37. Omasu, F, Nakano, Y, Ichiki, T (2005) Measurement of the electrophoretic mobility of sheep erythrocytes using microcapillary chips. Electrophoresis 26: pp. 1163-7 CrossRef
  38. Chen, J, Zhang, J, Zhao, Y, Li, J, Fu, M (2009) Integrin beta3 down-regulates invasive features of ovarian cancer cells in SKOV3 cell subclones. J Cancer Res Clin Oncol 135: pp. 909-17 CrossRef
  39. Soumaoro, LT, Uetake, H, Higuchi, T, Takagi, Y, Enomoto, M, Sugihara, K (2004) Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 10: pp. 8465-71 CrossRef
  40. Weidner, N, Folkman, J, Pozza, F, Bevilacqua, P, Allred, EN, Moore, DH (1992) Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84: pp. 1875-87 CrossRef
  41. Landis, JR, Koch, GG (1977) The measurement of observer agreement for categorical data. Biometrics 33: pp. 159-74 CrossRef
  42. Greiner, M, Pfeiffer, D, Smith, RD (2000) Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prev Vet Med 45: pp. 23-41 CrossRef
  43. Weis, SM, Cheresh, DA (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17: pp. 1359-70 CrossRef
  44. Yanagisawa, H, Schluterman, MK, Brekken, RA (2009) Fibulin-5, an integrin-binding matricellular protein: its function in development and disease. J Cell Commun Signal 3: pp. 337-47 CrossRef
  45. Albig, AR, Neil, JR, Schiemann, WP (2006) Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res 66: pp. 2621-9 CrossRef
  46. Scholler, N, Urban, N (2007) CA125 in ovarian cancer. Biomark Med 1: pp. 513-23 CrossRef
  47. Aggarwal, P, Kehoe, S (2010) Serum tumour markers in gynaecological cancers. Maturitas 67: pp. 46-53 CrossRef
  48. Bolocan, A, Ion, D, Ciocan, DN, Paduraru, DN (2012) Prognostic and predictive factors in colorectal cancer. Chirurgia (Bucur) 107: pp. 555-63
  49. Bhat, K, Wang, F, Ma, Q, Li, Q, Mallik, S, Hsieh, TC (2012) Advances in biomarker research for pancreatic cancer. Curr Pharm Des 18: pp. 2439-51 CrossRef
  50. Gadducci, A, Cosio, S, Carpi, A, Nicolini, A, Genazzani, AR (2004) Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother 58: pp. 24-38 CrossRef
  51. Henrotin, Y, Gharbi, M, Mazzucchelli, G, Dubuc, JE, Pauw, E, Deberg, M (2012) Fibulin 3 peptides Fib3-1 and Fib3-2 are potential biomarkers of osteoarthritis. Arthritis Rheum 64: pp. 2260-7 CrossRef
  52. Pass, HI, Levin, SM, Harbut, MR, Melamed, J, Chiriboga, L, Donington, J (2012) Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 367: pp. 1417-27 CrossRef
  53. Piura, E, Piura, B (2010) Autoantibodies to tumor-associated antigens in breast carcinoma. J Oncol 2010: pp. 264926 CrossRef
  
• 刊物主题：Cancer Research; Oncology; Stem Cells; Animal Models; Internal Medicine;
• 出版者：BioMed Central
• ISSN：1471-2407

文摘

Background Fibulin-4, a member of the fibulin family of extracellular glycoproteins, is implicated in the progressions of some cancers. However, no information has been available to date regarding the function of fibulin-4 in ovarian carcinoma progression. Methods In this study, fibulin-4 mRNA and protein expression in normal ovarian tissue, ovarian tumor, high invasive subclones and low invasive subclones were evaluated by immunohistochemistry and real time reverse transcriptase-polymerase chain reaction (RT-PCR). The serum levels of fibulin-4, cancer antigen 125 (CA-125) and cerbohydrate antigen 199 (CA19-9) in patients with ovarian tumor were measured by enzyme-linked immunosorbent assay and electrochemiluminescent immunoassay. To assess the angiogenic properties of fibulin-4, vascular endothelial growth factor (VEGF) expression and tumor microvessel density were analyzed in ovarian carcinoma by immunohistochemistry. Results Fibulin-4 expression was upregulated in ovarian carcinoma, and positively correlated with MVD and VEGF expression. Fibulin-4 overexpression was significantly associated with advanced stage, low differentiation, lymph node metastasis and poor prognosis in patients with ovarian cancer. The serum levels of fibulin-4, CA-125 and CA19-9 in patients with ovarian carcinoma were much higher than those with benign ovarian tumors and normal controls. Compared to CA-125 and CA19-9, fibulin-4 had better diagnostic sensitivity and specificity. Conclusions Fibulin-4 is a novel gene that is found overexpressed in ovarian cancer and associated with poor prognostic clinicopathologic features. This study shows that fibulin-4 may serve as a new prognostic factor and as a potential therapeutic target for patients with ovarian cancer in the future.